Fig. 1: Clinical validity classifications of candidate susceptibility genes associated with syndromic or familial breast and ovarian cancer

(a) Clinical validity classifications of 31 gene–disease pairs associated with syndromic or familial breast cancer susceptibility. Consensus genetic and experimental evidence scores are depicted for each gene–disease relationship wherein a Limited preliminary classification scored 0.1–6 total points, a Moderate preliminary classification had 7–11 total points, a Strong preliminary classification scored 12–18 total points, and a Definitive classification scored 12–18 total points and achieved replication over time (indicated by r/t). (b) Clinical validity classifications of 32 gene–disease pairs associated with syndromic or familial ovarian cancer susceptibility.